Overview

Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

A combined Phase Ib and IIa randomized, placebo-controlled, double-blind study of VM-1500 in healthy subjects and in patients with HIV-1 infection that are antiretroviral therapy naïve.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Viriom

Treatments:

Antiviral Agents